Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

Experimental Hematology

Volumn 37, Issue 8, 2009, Pages 956-968

  Abe, Yu ^a   Muto, Masato ^b   Nieda, Mie ^b   Nakagawa, Yasunori ^a   Nicol, Andrew ^c   Kaneko, Touru ^d   Goto, Shigenori ^d   Yokokawa, Kiyoshi ^e   Suzuki, Kenshi ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b Medinet Medical Institute   (Japan)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Seta Clinic Group   (Japan)

^e Medinet Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; DEXAMETHASONE; DOXORUBICIN; INTERFERON; INTERLEUKIN 2; M PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELPHALAN; PREDNISOLONE; RANIMUSTINE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THERAPY EFFECT;

ADULT; AGED; BLOOD CELLS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TREATMENT OUTCOME;

EID: 67650032911     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.04.008     Document Type: Article

References (35)

1. Attal M., Harousseau J.L., Atoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335 (1996) 91-97
2. Smyth M.J., Godfrey D.I., and Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2 (2001) 293-299
3. Kelly J.M., Darcy P.K., Markby J.L., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3 (2002) 83-90
4. Ferrarini M., Ferrero E., Dagna L., Poggi A., and Zocchi M.R. Human γδ T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 23 (2002) 14-18
5. Kabeliz D., Wesch D., Pitters E., and Zöller M. Potential of human γδ T lymphocytes for immunotherapy of cancer. Int J Cancer 112 (2004) 727-732
6. Lopez R.D. Human γδ-T cells in adoptive immunotherapy of malignant and infectious disease. Immunol Res 26 (2002) 207-221
7. Mariani S., Muraro M., Pantaleoni L., et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19 (2005) 664-670
8. Kabeliz D., Wesch D., Pitters E., and Zoller M. Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112 (2004) 727-732
9. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 375 (1995) 155-158
10. Bukowski J.F., Morita C.T., and Brenner M.B. Human γδ T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11 (1999) 57-65
11. Kunzmann V., Bauer E., and Wilhelm M. γ/δ T-cell stimulation by pamidronate. N Engl J Med 340 (1999) 737-738
12. Kunzmann V., Bauer E., Feurle J., Weissinger F., Tony H.P., and Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96 (2000) 384-392
13. Dieli F., Vermijlen D., Fulfaro F., et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67 (2007) 7450-7457
14. Märten A., Lilienfeld-Toal M., Büchler M.W., and Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for δ2 γ/δ T cells. J Immunother 30 (2007) 370-377
15. Mattarollo S.R., Kenna T., Nieda M., and Nicol A.J. Chemotherapy and zoledronate sensitize solid tumor cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 56 (2007) 1285-1297
16. Davodeau F., Peyrat M.A., Hallet M.M., et al. Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors. J Immunol 151 (1993) 1214-1223
17. Selin L.K., Stewart S., Shen C., Mao H.Q., and Wilkins J.A. Reactivity of gamma delta T cells induced by the tumor cell line RPMI 8226: functional heterogeneity of clonal population and role of GroEL heat shock proteins. Scand J Immunol 36 (1992) 107-117
18. Tokuyama H., Hagi T., Mattarollo S.R., et al. Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-Rituximab and trastuzumab. Int J Cancer 112 (2008) 2526-2534
19. Wilhelm M., Kunzmann V., Eckstein S., et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102 (2003) 200-206
20. Kobayashi H., Tanaka Y., Yagi J., et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56 (2007) 469-476
21. Caccamo N., Meraviglia S., Ferlazzo V., et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vγ9Vδ2 naïve, memory and effector T cell subsets. Eur J Immunol 35 (2005) 1764-1772
22. Gioia C., Agrati C., Casetti R., et al. Lack of CD27-CD45RA-Vγ9Vδ2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol 168 (2002) 1484-1489
23. Kondo M., Sakuta K., Noguchi A., et al. Zoledronate facilitates large-scale ex vivo expansion of functional δ2 T cells from cancer patients for use in adaptive immunotherapy. Cytotherapy 136 (2008) 159-167
24. Sasawatari S., Tadaki T., Isogai M., et al. Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC. Immunol Cell Biol 84 (2006) 512-521
25. Bauer S., Groh V., Wu J., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
26. Das H., Groh V., Kuijl C., et al. MICA engagement by human Vγ9Vδ2 T cells enhances their antigen-dependent effector function. Immunity 15 (2001) 83-93
27. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., and Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci U S A 96 (1996) 6879-6884
28. Kryczek I., Wei S., Zou L., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178 (2007) 6730-6733
29. Dieli F., Gebbia N., Poccia F., et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102 (2003) 2310-2311
30. Jinushi M., Takehara T., Tatsumi T., et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43 (2005) 1013-1020
31. Kato Y., Tanaka Y., Hayashi M., Okawa K., and Minato N. Involvement of CD166 in the activation of human γδ T cells by tumor cells sensitized with nonpeptide antigens. J Immunol 177 (2006) 877-884
32. Moser B., and Brandes M. γδ T cells: an alternative type of professional APC. Trends Immunol 27 (2006) 112-118
33. Girlanda S., Fortis C., Belloni D., et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 65 (2005) 7502-7508
34. Carbone E., Neri P., Mesuraca M., et al. HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105 (2005) 251-258
35. Groh V., Wu J., Yee C., and Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738